- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Vitiligo Could Be a Marker of Efficacy for Melanoma Drugs, Study Indicates
The retrospective analysis conducted in stage 3 and 4 immunotherapy-treated melanoma patients found that the development of vitiligo could serve as a clinical marker for effective antimelanoma immunity and improved clinical outcome.
The development of vitiligo in melanoma patients on immunotherapy may predict improved survival, according to findings from a systematic review and meta-analysis.
In 137 studies reported between 1995 and 2013 and including 5737 patients with stage 3 to 4 melanoma who were treated with immunotherapy, the pooled cumulative incidence of vitiligo was 3.4%. In those with vitiligo for whom individual patient data were available, both progression-free and overall survival were significantly improved, compared with those without vitiligo after researchers adjusted for age and sex (hazard ratio, 0.51 and 0.25, respectively), Hansje-Eva Teulings, MD, of the University of Amsterdam and her colleagues reported online January 19 in the Journal of Clinical Oncology.
Link to the complete article on Oncology Practice:
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
